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Abstract 
Polycystic kidney disease (PKD) is a prevalent genetic disorder, characterized by the formation 
of kidney cysts that progressively lead to kidney failure. The currently available drug tolvaptan is 
not well tolerated by all patients and there remains a strong need for alternative treatments. The 
signaling rewiring in PKD that drives cyst formation is highly complex and not fully understood.  
As a consequence, the effects of drugs are sometimes difficult to predict. We previously 
established a high throughput microscopy phenotypic screening method for quantitative 
assessment of renal cyst growth. Here, we applied this 3D cyst growth phenotypic assay and 
screened 2320 small drug-like molecules, including approved drugs. We identified 81 active 
molecules that inhibit cyst growth. Multi-parametric phenotypic profiling of the effects on 3D 
cultured cysts discriminated molecules that showed preferred pharmacological effects above 
genuine toxicological properties. Celastrol, a triterpenoid from Tripterygium Wilfordii, was 
identified as a potent inhibitor of cyst growth in vitro. In an in vivo iKspCre-Pkd1lox,lox mouse 
model for PKD, celastrol inhibited the growth of renal cysts and maintained kidney function. 
 
Introduction 
Autosomal Dominant Polycystic kidney disease (ADPKD) affects approximately 1 in 2500 
people (Willey, et al., 2017). Patients will develop renal failure as a result of progressive growth 
of renal cysts, which interfere with normal kidney function. The disease is caused by mutations 
in the PKD1 or PKD2 gene, encoding polycystin-1 or polycystin-2, respectively (Torres, et al., 
2007). These proteins are expressed in several cellular compartments and form multimeric 
protein complexes, that modulate multiple signaling pathways, which in concert control essential 
cellular functions such as proliferation, apoptosis, cell adhesion and differentiation (Torres and 
Harris, 2014). However, how mutations in the PKD genes cause the development of renal cysts 
is still not fully understood. In addition, we know little about how the signaling pathways 
involved in driving renal cyst growth are interconnected, and how they contribute to this process. 
As a consequence, it is also poorly understood how certain compounds that are under 
investigation for their therapeutic potential, exert their ‘cyst-reducing’ properties and why certain 
therapies become less effective at the more progressive stages.  
Currently only one drug, tolvaptan (Jinarc), is marketed for the treatment of PKD. This drug has 
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patients (Torres, et al., 2012). Because PKD patients require therapy for many decades, it is 
critical to improve the balance between side-effects and preventing cyst growth. A possibility to 
achieve this goal is by combination therapy with multiple effective drugs, allowing for dose 
reduction, or the identification of more effective drugs with fewer side effects. 
To identify new drug candidates that prevent cyst growth, we previously developed a 3D cyst 
culture-based high-throughput screening platform, which can be used to screen large libraries of 
molecules for the identification of cyst-inhibiting compounds (Booij, et al., 2017). This 3D assay 
uses phenotypic profiling of cysts as a measure of compound efficacy. Phenotypic screening can 
enable the identification of effective molecules irrespective of their mechanism of action and 
without a comprehensive understanding of the pathophysiology and can be effective at 
identifying first-in-class treatments (Swinney, 2013).  
Here, we applied this screening platform to screen 2320 drug-like molecules to identify effective 
inhibitors of cyst-growth. Using phenotypic profiling, molecules were pre-selected for in vivo 
testing based on desirable activity and safety. In two independent experiments, we report the 
potent activity of celastrol, a triterpenoid from Tripterygium Wilfordii, at inhibiting cyst growth 
and maintaining kidney function in an iKspCre-Pkd1lox,lox mouse model. 
 
Results 
Screening a small-molecule library to identify inhibitors of cyst growth 
To identify new molecules that can potentially be used for the treatment of PKD, we screened a 
SPECTRUM compound library, consisting of 2320 molecules, including kinase inhibitors, 
natural molecules and FDA-approved drugs. We cultured epithelial cysts from mIMCD3 cells 
with short hairpin-mediated reduced Pkd1 expression (mIMCD3 shPkd1) in 384-well plates in 
protein hydrogels. Forskolin is known to enhance cyst swelling in vitro (Mangoo-Karim, et al., 
1989) and is known to activate adenylyl cyclase to induce cyclic adenosine monophosphate 
(cAMP) production, a central mediator of cystogenesis (Devuyst and Torres, 2013). Following 
exposure to forskolin, we co-exposed the cysts to control compounds or test compounds of the 
SPECTRUM library at 1 µM (Supplementary Figure S1). After imaging and calculating cyst size 
using phenotypic measurements, we ranked the molecules on their potency to inhibit cyst growth 
as presented in Figure 1A, top panel. As criterion for hit selection, molecules were selected that 
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As a result, 81 cyst-inhibiting hits were identified (Figure 1A, bottom panel). All hits were re-
screened at six concentrations in triplicate wells using RNA-guided FokI nuclease-mediated 
(Tsai, et al., 2014) Pkd1-knockout cells (mIMCD3 Pkd1-/-; Supplementary Figure S2A and B), 
confirming the activity of 66.6% of the molecules (54 molecules with cyst growth 
inhibition  >50% at 1 µM). 
To get more insight into the molecules that were active in our screen, we listed the molecules 
according to their bioactivities described in the manufacturer’s datasheet. It is important to note 
that some molecules do not belong exclusively to one class and may have dual bioactivities. An 
evaluation of the 81 hits revealed that the largest group of selected hits were molecules known to 
have an antineoplastic mechanism of action (25.9% of our hits compared to 4.9% of the library; 
Figure 1B and C).  
Since most ADPKD patients will need drug treatment for decades, antineoplastic drugs are 
unlikely to become therapeutic candidates. Therefore, we applied linear discriminant analysis 
(LDA) on measured phenotypic parameters (with correlation <0.85), to discriminate known toxic 
molecules from stimulated- and unstimulated controls. This strategy allowed us to separate most 
antineoplastic molecules from molecules with a different mode of action (Supplementary Figure 
S3A and B). For all molecules, we determined the proximity in feature space to the unstimulated 
control group as a measure of desirable efficacy. Supplementary Figure S3C presents this 
distance as a color scale from yellow to blue. While most anti-infective and antihelmintic 
retained their favorable activity (distance <50 at 1 µM), most antineoplastic molecules remained 
distant from the favorable (and small) control cysts phenotype. 
 
Celastrol inhibits cyst growth dose-dependently 
Based on these results, we found that celastrol (Figure 2A), a triterpenoid extracted from 
Tripterygium Wilfordii (Wong, et al., 2012), and pyrvinium pamoate, an antihelmintic drug (Jung, 
1976) and WNT inhibitor (Thorne, et al., 2010) (Supplementary Figure S4A), were very potent 
at inhibiting cyst growth in vitro. Celastrol appeared to induce phenotypes associated with 
toxicity only at high concentrations (≥316 nM), and potently inhibited forskolin-induced cyst 
growth at 100 nM (Figure 2B and C), with effects becoming apparent after 48-h co-treatment 
with forskolin (Supplementary Figure S5A). We also report that at concentrations up to 10 µM, 
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concentration (Supplementary Figure S5B), likely because of low expression of the Vasopressin 
V2 receptor in this particular cell line (unpublished). Interestingly, several closely-related 
structural analogues of celastrol, dihydrocelastrol and dihydrocelastryl diacetate, displayed a 
similar activity profile (Supplementary Figure S5C and D). Pyrvinium pamoate showed no 
indication of toxicity even at high concentrations (Supplementary Figure S4B).  
To determine if the inhibition shown by celastrol was dependent on cAMP induction by forskolin, 
we assessed whether it could inhibit cyst growth in the absence of forskolin. While more 
variation within wells was observed within this long-duration assay (attributable to the necessity 
to refresh compounds and culture media), we observed activity of celastrol at 100 nM, but not 10 
nM, when compared to solvent control (Figure 2D). 
 
Celastrol inhibits cyst growth in vivo in iKspCre-Pkd1lox,lox mice and prevents decline of kidney 
function 
To investigate whether the findings in vitro could be translated to a response in vivo, we tested 
both celastrol and pyrvinium pamoate in a iKspCre-Pkd1lox,lox mouse model, where tamoxifen 
was used to inactivate the Pkd1 gene at postnatal day 10 (P10) and P11, to induce rapid cyst 
formation (Lantinga-van Leeuwen, et al., 2007; Leonhard, et al., 2016). Treatment with 
pyrvinium pamoate from P13 appeared to be toxic at 1mg/kg/day, and lower dosages did not 
affect PKD progression in this model (Supplementary Figure S4C and D). We therefore did not 
further pursue this compound as a possible candidate for PKD treatment. By contrast, celastrol 
treatment inhibited PKD progression in two separate experiments (Figure 3). The effects of 
celastrol were first measured at 1 mg/kg/day (7 mice) from P13 to P27, and, even though 
changes in bodyweight were observed initially, between P13 and P18, celastrol appeared to be 
well tolerated. In a subsequent independent experiment, we observed similar effects of celastrol 
at 0.5 mg/kg/day (8 mice) but not at 0.2 mg/kg/day (8 mice) (Supplementary Figure S6A). In line 
with the in vitro findings, celastrol strongly protected kidney function, while lowering cyst 
burden (Figure 3A-C and Supplementary Figure S6B‒E). Renal fibrosis, an important hallmark 
of ADPKD, is largely driven by activin or TGF-β mediated Smad2/3 activation, resulting in the  
transcription of target genes including collagens, Plasminogen activator inhibitor-1 and 
fibronectin-1.  We did not find evidence that the Smad2/3 activation underlies cystic expansion 
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PKD mice (Supplementary Figure S7A) (Hassane, et al., 2010; Leonhard, et al., 2016). We 
observed more collagen deposition in PKD kidneys (Figure 3D and E) as well as increased 
expression of Pai1, Col1a1, and Fn1(EDA) (Supplementary Figure S7A). In celastrol-treated 
animals at 0.5 and 1.0 mg/kg/day, this expression pattern could partially be restored and PKD-
associated fibrosis was lowered (Figure 3D and E). Recently, it has been shown that celastrol 
reduces renal fibrosis in an Unilateral Ureteral Obstruction model, by enhancing the expression 
of the anti-fibrotic Cannabinoid Receptor 2 (Cb2r) gene (Tang, et al., 2018). We therefore 
analyzed Cb2r expression (Supplementary Figure S7) but show that renal fibrosis in a PKD 
context increases Cb2r expression. The celastrol-treated animals consistently show the opposite 
expression pattern, which likely reflects the lower cystic load in the celastrol treated animals. 
 
Subtle effects of celastrol on PKD-related signaling 
Celastrol has been investigated for other indications where it has shown promising responses, 
such as inflammatory disorders, cancer and obesity (Kannaiyan, et al., 2011; Liu, et al., 2011, 
2015; Venkatesha, et al., 2016). However, the mechanism by which celastrol may affect cyst 
growth is unclear and we therefore investigated its effects on known PKD-associated signaling 
(pCREB, pS6, pSTAT3, pERK1/2). Both, in tissue sections and 3D cyst cultures (Figure 4A‒C), 
we found no clear effects of celastrol treatment on the expression pattern of these proteins. 
Western blotting was used to quantify the expression levels of pS6, pSTAT3, and pERK1/2. 
Although not statistically significant, we observed a slight reduction of pS6 levels in tissue 
sections following celastrol exposure; this could indicate an effect of celastrol on mTOR activity 
(Figure 4B and C). 
Since increased proliferation is an important hallmark in ADPKD, we stained kidney sections of 
PKD mice treated with vehicle or celastrol with the proliferation marker Ki67. Scanned images 
of these sections were used to set-up an automated nuclear segmentation and Ki67+ nuclei 
identification method to determine the proliferation indices (Figure 4D and Supplementary 
methods). The data indicates that there was no visible effect of celastrol on proliferation at the 
time the mice were sacrificed. 
In renal epithelial cells subcellular polarized expression of various ion pumps, including  
Na+/K+-ATPase, control ion gradients and osmotic pressure, which are important for fluid 
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(Terryn, et al., 2011).  A shift from basolateral in normal cells to apical in cystic epithelial cells 
has been reported (Wilson, et al., 2000). However, others reported that the localization in cystic 
cells remains lateral and to some extent basal but not apical (Brill, et al., 1996). We found mostly 
basolateral, and cytoplasmic Na+/K+-ATPase expression in 3D cultured cysts and in kidneys of 
PKD mice (Supplementary Figure S8). Fluorescent immunohistochemistry on 3D cultured cysts 
confirmed lateral and to lesser extent basal expression of Na+/K+-ATPase, but no apical 
expression (Supplementary Figure S9). In renal cysts, the Na+/K+-ATPase expression appears to 
be lower than in healthy tubules, which was confirmed by western blotting (Supplementary 
Figure S8C). The pattern of Na+/K+-ATPase staining was not affected by celastrol treatment, 
although the expression tends to be reversed to wild type levels, which may be a reflection of the 
lower cystic load in celastrol treated animals, this reduction was not found to be statistically 
significant (Supplementary Figure S8C).  
 
Discussion 
To discover new drug-like molecules that prevent cystogenesis, we screened a SPECTRUM 
compound library containing 2320 compounds. Hits were selected and compounds with 
potentially undesirable characteristics were further eliminated using multiparametric phenotypic 
profiling of the compound effect. The triterpenoid celastrol and the antihelmintic drug pyrvinium 
pamoate were selected for further evaluation in an iKspCre-Pkd1lox,lox mouse model.  
Besides its antihelmintic activity, pyrvinium pamoate is thought to affect WNT/β-catenin and 
may have potent effects against certain types of cancer (Esumi, et al., 2004; Momtazi-Borojeni, 
et al., 2018; Polosukhina, et al., 2017; Venerando, et al., 2013; Zhang, et al., 2017). We found 
that pyrvinium pamoate did not induce beneficial responses in PKD mice, and appeared to cause 
toxic effects at higher doses. This molecule was therefore not further pursued for treatment of 
PKD. Since pyrvinium pamoate is used to treat intestinal infections (Smith, et al., 1976), and not 
designed for i.p. administration, there is a possibility that it cannot reach the kidneys in sufficient 
concentration to prevent cyst growth while not affecting other tissue types and organs. The toxic 
effects observed with the dose 1 mg/kg/day in mice were not predicted based on the phenotypic 
analysis of cultured cysts. While it is possible that this toxicity is related to effects of pyrvinium 
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that further investigation and fine-tuning of the differential phenotypic effects of toxic substances 
could help to exclude such substances in the future.  
While pyrvinium pamoate did not show a beneficial response in mice, celastrol caused a strong 
reduction in the growth of renal cysts in vivo, while preventing the deterioration of kidney 
function. A recent study also confirmed the cyst-reducing effects by celastrol in another model 
for PKD (Chang, et al., 2018). Initially, we observed a reduction in body weight after treatment 
with celastrol. However, celastrol appeared to be well tolerated and the reduction in body weight 
could also be related to the reported role of celastrol as a leptin sensitizer (Liu, et al., 2015). 
While this finding may introduce bias (food restriction is known to ameliorate cystogenesis in 
patients (Warner, et al., 2016)), we nevertheless consider it unlikely that anti-obesity effects 
would explain such profound effects in vivo and particularly not efficacy in vitro. 
Phenotypic profiling of 3D cultured cysts and the subsequent evaluation in mice allowed for the 
identification of celastrol as an inhibitor of cyst growth irrespective of its mechanism of action. 
To determine through which mechanisms celastrol can affect cyst growth in vitro and in vivo, we 
studied the effects on signaling pathways associated with PKD on 3D-cultured cysts and tissue 
sections. Both in tissue sections and cultured cysts, we observed no effects on pCREB, pSTAT3 
and pERK, and, although we observed a small not statistically significant effect of celastrol on 
pS6 in PKD kidneys, this can also be a reflection of the milder cystic phenotype of the celastrol-
treated animals. In addition, Cb2r and Na+/K+-ATPase expression studies were not indicative for 
the mechanism by which celastrol reduces PKD progression. We could confirm a role of TGF-β 
related signaling in PKD mice, but failed to detect this same involvement in 3D cyst cultures, 
indicating that this pathway is not causative for cyst growth in this model. Since the 3D cysts are 
cultured in an already collagen-rich extracellular matrix, this model may not be optimal for 
studying fibrosis during cystogenesis.  
A variety of studies suggested a large number of signaling pathways that may be affected by 
celastrol including HSP90/Cdc37 (Dal Piaz, et al., 2015; Hieronymus, et al., 2006) and NFκB 
(Lee, et al., 2006) (for a literature overview see Supplementary Table S2). We therefore consider 
it likely that celastrol affects cystogenesis by a multi-target mechanism. This idea was further 
supported by recent research by Zhou et al. (2016), where 66 celastrol-binding proteins were 
identified, which function in various different processes, including (redox-) metabolism and the 
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celastrol (and other triterpenoids) with thiol groups in many proteins (Liby, et al., 2007; 
Salminen, et al., 2010; Zhou, et al., 2016). Interestingly, similar Michael acceptor properties 
have been reported for curcumin (Na and Surh, 2006), a molecule that also delays cystogenesis 
in mice (Leonhard, et al., 2011). Because these molecules may have different affinity towards 
different thiol residues, it is possible that they affect other proteins and pathways as a result of 
concentration changes (Liby, et al., 2007). Celastrol is also known to have antioxidant activity 
(Wang, et al., 2014), and may therefore reduce kidney damage by induction of cytoprotective 
genes, as reported for curcumin (Balogun, et al., 2003), which can in turn ameliorate 
cystogenesis (Happe, et al., 2009; Malas, et al., 2017; Takakura, et al., 2009).  
In conclusion, using phenotypic screening, we have identified celastrol as a potent inhibitor of 
cyst growth. We confirmed the efficacy of celastrol in a juvenile PKD model where it potently 
protected kidney function and lowered cyst burden. The phenotypic screening approach allowed 
for the identification of this molecule without knowing its mechanism of action, which is likely 
not specific for one target. While additional experiments to determine the mechanism of action 
of celastrol and to establish its safety and efficacy profile are warranted, celastrol may prove to 
be an interesting treatment option for PKD. 
 
Materials and methods 
Additional detailed descriptions of the experimental procedures are included in Supplementary 
material. 
 
3D cyst culture procedure 
Cyst culture and screening were performed as described previously (Booij, et al., 2017). Briefly, 
cryopreserved mIMCD3 shPkd1 or mIMCD3 Pkd1-/- cells were quick-thawed and grown in 
culture medium (DMEM/F12 Ham’s, supplemented with FBS and antibiotics) for 72 hours. Cells 
were trypsinized and mixed with Cyst-Gel (OcellO) and plated in 384-well plates (Greiner Bio-
One). After addition of culture medium, cysts were allowed to form during 72 h (shPkd1) or 96 h 
(Pkd1-/-) and subsequently exposed to forskolin (Calbiochem) and test compounds for 72 h. 
Cysts were thereafter fixed and simultaneously stained for F-actin and nuclei for 12‒24 h at 4°C. 
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Pathway 855 microscope (BD Bioscience) or ImageXpress Micro XLS (Molecular Devices), 
with a 4× objective. 
 
Image and data analysis 
Image stacks for each well were analyzed and phenotypes were quantified using Ominer 
software (OcellO) integrated in KNIME Analytics Platform (http://www.knime.org) 
(Supplementary Figure S1A and C). The 450 phenotypic measurements were z-score normalized 
to plate median or normalized to percent of control. Linear discriminant analysis (LDA) was 
performed using the 83 least correlating phenotypic parameters (Pearson product-moment 
correlation coefficient <0.85). LDA was trained on unstimulated (solvent), stimulated (forskolin-
treated), and known cytotoxic molecules (daunorubicin, doxorubicin, staurosporin, gambogic 
acid, epirubicin, at 1 µM) and the trained model was applied to all data. The two resulting linear 
discriminants were scaled and a small absolute distance (<50) to the unstimulated control group 
was considered as desirable efficacy. 
 
Compounds 
A molecule library containing 2320 compounds (SPECTRUM 2320) was obtained from 
MicroSource Discovery Systems. Compounds were pre-dissolved to 10 mM in DMSO (Biosolve) 
and final DMSO content was kept constant at a well-tolerated 0.2% (v/v) for all in vitro 
experiments. Celastrol was derived from this library and performed equally well compared to 
celastrol obtained from another source (Sigma Aldrich). 
 
Animal procedures 
The local animal experimental committee of the Leiden University Medical Center (LUMC) and 
the Commission Biotechnology in Animals of the Dutch Ministry of Agriculture approved all 
animal experiments performed. Kidney-specific, tamoxifen-inducible Cre-Pkd1lox mice 
(iKspCre-Pkd1lox,lox) (Lantinga-van Leeuwen, et al., 2006; Lantinga-van Leeuwen, et al., 2007) 
received 15 mg/kg Tamoxifen at P10 and P11 to inactivate Pkd1 to cause rapid cyst formation. 
Mice received i.p. injections of celastrol, pyrvinium pamoate, or vehicle (5% DMSO + 10% 
Kolliphor EL in PBS) between P13 and P27. Mice were euthanized at P27 after blood sample 
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snap frozen or embedded in paraffin. Image scans of Periodic acid-Schiff (PAS)- stained kidney 
sections were analyzed by an investigator blinded to the treatment. The fibrotic index was 
calculated as done previously on the basis of Sirius Red staining (Leonhard, et al., 2016). 
 
Immunohistochemistry 
Samples were fixated with formaldehyde and embedded in paraffin. Samples were subsequently 
deparaffinised and subjected to heat-mediated antigen retrieval. Sections were blocked with 0.2% 
H2O2 for 20 min and subsequently pre-incubated for 1 h with 5% normal goat serum in 1% BSA 
in PBS. Sections were then incubated O/N with anti-pSTAT3 (1:75, Cell Signaling Technology, 
no. 9145), anti-p-rpS6 (1:100, Cell Signaling Technology, no. 2215), anti-pERK1/2 (1:400, Cell 
Signaling Technology, no. 4370), anti-Ki67 (1:3000, Nova Castra, NCL Ki67p), anti-pCREB 
(1:800, Cell Signaling Technology, no. 9198), or anti-Na+/K+-ATPase (1:6400, Abcam, 
ab76020). Immune reactions were revealed using diaminobenzidine and hematoxylin, after 
incubation of sections with horseradish peroxidase.  
 
Western blotting 
NaF, Na2VO4, and protease inhibitor cocktail (Roche) were used to inhibit phosphatase and 
protease activity. Kidneys were homogenized with RIPA without detergents using Magnalyser 
technology (Roche) followed by sonication. RIPA with detergents was added and incubated for 
45 min at 4°C, after which lysates were centrifuged and supernatants were stored at -80°C. 
Lysate was subsequently used for SDS-PAGE and immunoblotting. Membranes were blocked 
for 1 h with 25% sea block blocking buffer (Thermo Fisher Scientific/Pierce) and incubated O/N 
with anti-pSTAT3 (1:1000), anti-p-rpS6 (1:2000), anti-pERK1/2 (1:1000), anti-Na+/K+-ATPase 
(1:10.000),  or anti-α-tubulin (1:2000).  DyLight reagents (Perbio Science, no.35571 or no.35518) 
were used as secondary antibody. Detection and densitometric analysis were carried out using 
Odyssey Infrared Imaging System (Westburg). 
 
Proliferation index 
Kidney sections were stained with anti-Ki67 as described above and scanned for image analysis. 
Image segmentation and subsequent object extraction was performed using Ominer software 













 user on 16 July 2019
 12 
eliminate variation in staining intensity between the outer medulla and cortex, digital background 




Statistical analyses were performed in Graphpad Prism 7 software using ANOVA with Dunnett’s 
multiple comparison’s test unless otherwise stated in figure legends. Results were considered 
statistically significant for p<0.05. 
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Figure Legends 
Figure 1 Screening a small-molecule library to identify inhibitors of cyst growth. (A) 2320 
molecules were ranked according to inhibitory effect on mIMCD3 shPkd1 cyst growth (z-score 
normalized to plate median). Molecules inhibiting cyst growth relative to forskolin-stimulated 
control (“Stimulated”) included positive control molecules, as indicated by colored circles in the 
enlarged cut-out. For control molecules, error bars represent standard deviations (SD). For all 
other molecules, error bars represent ½*difference between two replicate wells. (B) Many 
molecules contained in the library have an antibacterial or antineoplastic mechanism of action. 
Since for some natural molecules the mechanism of activity is not elucidated, the bioactivity is 
listed as “unknown”. (C) The selected 81 cyst growth-inhibiting hits were markedly enriched in 


















 user on 16 July 2019
 18 
Figure 2 Celastrol inhibits cyst growth dose-dependently. (A) Celastrol inhibits mIMCD3 Pkd1-
/- cyst growth. At the highest concentrations (316 and 1000 nM), cyst size is lower than 
unstimulated control, possibly corresponding to effects shown in B in linear discriminant 2. 
These experiments were repeated at least three times. (B) LDA plot showing efficacy (linear 
discriminant 1) and toxicity (linear discriminant 2) of celastrol using multiparametric phenotypic 
measurements on mIMCD3 Pkd1-/- cysts. At the left (ringed in blue), the forskolin stimulated 
large cysts. At the right (ringed in black), the unstimulated small cysts. Larger dot sizes 
correspond to higher compound concentrations. Celastrol (red dots) is only toxic at the highest 
concentration. (C) Representative images of 3D-cultured mIMCD3 Pkd1-/- cysts (cytoskeleton, 
F-actin) co-exposed with 2.5 µM forskolin and celastrol at different concentrations, or vehicle 
control (stimulated, 2.5 µM forskolin). The 500×500px cut-out of images taken with the 
ImageXpress Micro XLS imager are shown for presentation purposes. (D) Long-term exposure 
with celastrol shows inhibition of spontaneous cyst growth over 13 days. The 1000×1000px cut-
out of (cytoskeleton, F-actin) images were taken with the BD Pathway 855 imager. Brightness 
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Figure 3 Celastrol inhibits cyst growth in vivo in iKspCre-Pkd1lox,lox mice and prevents decline 
of kidney function. The results presented here combined two independent experiments, where 
celastrol was first tested at 1 mg/kg/day and later at 0.2 and 0.5mg/kg/day, because the vehicle 
controls were highly similar. (A) Two-kidney weight as percentage of bodyweight of vehicle-
treated or celastrol-treated mice at P27. Data shown represent mean±SD and individual data 
points for all mice. Vehicle-treated (n=16), celastrol 0.2 mg/kg (n=7), 0.5 mg/kg (n=8), and 1.0 
mg/kg (n=7). (B) Blood urea nitrogen (BUN/Urea) given in mmol/L for vehicle- or celastrol-
treated mice as a measurement of kidney function plotted against cystic index, indicating in vivo 
cyst size (disease severity) measured in P27 kidneys after vehicle or celastrol treatment. Vehicle-
treated (n=16), celastrol 0.2 mg/kg (n=7), 0.5 mg/kg (n=8), and 1.0 mg/kg (n=7). (C) 
Representative images of renal histology of P27 kidneys showing that renal cysts were reduced 
after celastrol treatment for 0.5 and 1.0 mg/kg treatment groups, compared to vehicle. Additional 
tissue sections are presented in Supplementary Figure S6 to illustrate experimental variation. (D) 
Fibrotic index as measured by intensity of Sirius Red signal (normalized to vehicle control) for 
vehicle-treated (n=16), 0.2 mg/kg/day celastrol-treated (n=7), 0.5 mg/kg/day celastrol-treated 
(n=7), and 1.0 mg/kg/day celastrol-treated (n=7) mice. (E) Representative Sirius Red-stained 
sections of celastrol-treated (0.2, 0.5, and 1.0 mg/kg/day) P27 kidneys, compared to vehicle 
control. Statistical significance was assessed with ordinary one-way ANOVA with Dunnett’s 



















Figure 4 Subtle effects of celastrol on PKD-related signaling. (A) Representative images of 
sections of 3D-cultured mIMCD3 Pkd1-/- cysts, treated with solvent (DMSO), celastrol, or 
rapamycin and stained for pS6 (mTOR activity), pCREB, pSTAT3, and pERK1/2. Scale bar, 100 
µm. (B) Tissue sections after staining for pS6, pCREB, pSTAT3, and pERK1/2 of vehicle-
treated and celastrol-treated mice (1 mg/kg/day). To be able to judge the expression pattern of 
the proteins, images were made in areas that were either minimally cystic in vehicle-treated mice 
or cystic in vehicle- or celastrol-treated mice (scale bar, 50 µm). The expression pattern of the 
minimally cystic regions is comparable to the pattern in WT tissue sections (data not shown and 
(Leonhard, et al., 2011; Leonhard, et al., 2015)) where cystic and non-cystic tissue was present. 
(C) Western blotting and densitometric quantification of combined blots for pS6, pSTAT3, 
pERK1/2, and tubulin of vehicle-treated and celastrol-treated mice (1 mg/kg/day). Potential 
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were tested using Student’s t-test: *p<0.05, ‘ns’ indicates not statistically significant. (D) Ki67 
quantification. Upper panel shows processed inverted images of a Ki67-stained kidney section 
(yellow signal is Ki67 negative, blue signal is Ki67 positive) masking either the cortex (upper 
middle) or outer medulla (OM, upper right). Lower panel shows the raw signal of a section with 
Ki67 staining, including a magnification of the raw signal and processed signal showing the 
nuclear segmentation and Ki67-positive (blue) or Ki67-negative (yellow) nuclei. The 
quantification of the proliferation index (% of Ki67-positive nuclei) is shown at the right: vehicle 
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